Pfizer (PFE) option implied volatility flat amid the spread of coronavirus into CDC update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Cantor Fitzgerald Reiterates Overweight Rating on Pfizer (PFE) Following 4Q
January 29, 2020 7:04 AM ESTCantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $53.00 price target on Pfizer (NYSE: PFE) following the company's 4Q earnings report. PFE reported 4Q19 adjusted diluted EPS of $0.55, $0.03 lower than consensus.
PFE presented its 2020 sales and EPS guidance of $48.5-50.5B and... More
Pfizer (PFE) Trades at Session High, Up 1.2%
January 27, 2020 2:30 PM ESTPfizer (NYSE: PFE) Trades at Session High, Up 1.2%
... More